Search for

List of Strains Covered

Suggested search words: constipation diarrhea cough cancer ibs crohn mood stress allergy flu IL-10 obesity

ProbioticSellerStudy (Click to View)
Bacillus clausii N/R Enterogermina Results of treatment with Bacillus subtilis spores (Enterogermina) after antibiotic therapy in 95 patients with infection calculosis.
Bacillus clausii O/C Enterogermina Results of treatment with Bacillus subtilis spores (Enterogermina) after antibiotic therapy in 95 patients with infection calculosis.
Bacillus clausii SIN Enterogermina Results of treatment with Bacillus subtilis spores (Enterogermina) after antibiotic therapy in 95 patients with infection calculosis.
Bacillus clausii T Enterogermina Results of treatment with Bacillus subtilis spores (Enterogermina) after antibiotic therapy in 95 patients with infection calculosis.
Bacillus mesentericus (subtilis) TO-A AOR, Probiotic 3 [The efficiency of probiotics in the prevention of recurrent lower urinary tract infections and bacterial vaginosis].
Bifidobacterium lactis BB-12 Nestlé Protocol for a double-blind placebo-controlled trial to evaluate the efficacy of probiotics in reducing antibiotics for infection in care home residents: the Probiotics to Reduce Infections iN CarE home reSidentS (PRINCESS) trial.
Enterococcus faecium W54 Ecologic® AAD Enlisting Probiotics to Combat Recurrent Urinary Tract Infections in Women-A Military Strategy for Meeting the Challenge.
Lactobacillus casei Shirota Yakult Antimicrobial activity of intraurethrally administered probiotic Lactobacillus casei in a murine model of Escherichia coli urinary tract infection.
Lactobacillus casei Shirota Yakult Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies.
Lactobacillus fermentum ME-3 Reg'Activ Essential ME-3 Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and uropathogens.
Lactobacillus paracasei 8700:2 UltraFlora® Cold Support Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and uropathogens.
Lactobacillus plantarum 299v Jarrow Formulas Ideal Bowel Support Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and uropathogens.
Lactobacillus reuteri RC-14 RepHresh™ Pro-B™ Probiotic Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women.
Lactobacillus reuteri RC-14 RepHresh™ Pro-B™ Probiotic Non-Antibiotic Prophylaxis for Urinary Tract Infections.
Lactobacillus reuteri RC-14 RepHresh™ Pro-B™ Probiotic Oral probiotics and the female urinary microbiome: a double-blinded randomized placebo-controlled trial.
Lactobacillus reuteri RC-14 RepHresh™ Pro-B™ Probiotic Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 may help downregulate TNF-Alpha, IL-6, IL-8, IL-10 and IL-12 (p70) in the neurogenic bladder of spinal cord injured patient with urinary tract infections: a two-case study.
Lactobacillus reuteri RC-14 RepHresh™ Pro-B™ Probiotic Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a randomised controlled trial.
Lactobacillus reuteri RC-14 RepHresh™ Pro-B™ Probiotic Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a study protocol for a randomised controlled trial.
Lactobacillus reuteri RC-14 RepHresh™ Pro-B™ Probiotic Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies.
Lactobacillus reuteri RC-14 RepHresh™ Pro-B™ Probiotic Probiotics to prevent urinary tract infections: the rationale and evidence.
Lactobacillus rhamnosus GG Culturelle® <i>Lactobacillus rhamnosus</i> GG can protect malnourished children.
Lactobacillus rhamnosus GG Culturelle® Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and uropathogens.
Lactobacillus rhamnosus GG Culturelle® Bladder instillation for urinary tract infection prevention in neurogenic bladder patients practicing clean intermittent catheterization: A systematic review.
Lactobacillus rhamnosus GG Culturelle® Clinical indications for probiotics: an overview.
Lactobacillus rhamnosus GG Culturelle® Lactobacilli for prevention of urogenital infections: a review.
Lactobacillus rhamnosus GG Culturelle® Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a randomised controlled trial.
Lactobacillus rhamnosus GG Culturelle® Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a study protocol for a randomised controlled trial.
Lactobacillus rhamnosus GG Culturelle® Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies.
Lactobacillus rhamnosus GG Culturelle® Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial-PROSPECT: a pilot trial.
Lactobacillus rhamnosus GG Culturelle® Protocol for a double-blind placebo-controlled trial to evaluate the efficacy of probiotics in reducing antibiotics for infection in care home residents: the Probiotics to Reduce Infections iN CarE home reSidentS (PRINCESS) trial.
Lactobacillus rhamnosus GG Culturelle® Risk and Protective Factors for Gastrointestinal Symptoms associated with Antibiotic Treatment in Children: A Population Study.
Lactobacillus rhamnosus GG Culturelle® Use of Lactobacillus casei subspecies Rhamnosus GG and gastrointestinal colonization by Candida species in preterm neonates.
Lactobacillus rhamnosus GG Culturelle® Vaginal colonization by orally administered Lactobacillus rhamnosus GG.
Lactobacillus rhamnosus GR-1 RepHresh™ Pro-B™ Probiotic Disruption of urogenital biofilms by lactobacilli.
Lactobacillus rhamnosus GR-1 RepHresh™ Pro-B™ Probiotic Effects of probiotics on the recurrence of bacterial vaginosis: a review.
Lactobacillus rhamnosus GR-1 RepHresh™ Pro-B™ Probiotic Lactobacilli for prevention of urogenital infections: a review.
Lactobacillus rhamnosus GR-1 RepHresh™ Pro-B™ Probiotic Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women.
Lactobacillus rhamnosus GR-1 RepHresh™ Pro-B™ Probiotic Lactobacillus inhibitor production against Escherichia coli and coaggregation ability with uropathogens.
Lactobacillus rhamnosus GR-1 RepHresh™ Pro-B™ Probiotic Non-Antibiotic Prophylaxis for Urinary Tract Infections.
Lactobacillus rhamnosus GR-1 RepHresh™ Pro-B™ Probiotic Oral probiotics and the female urinary microbiome: a double-blinded randomized placebo-controlled trial.
Lactobacillus rhamnosus GR-1 RepHresh™ Pro-B™ Probiotic Oral probiotics can resolve urogenital infections.
Lactobacillus rhamnosus GR-1 RepHresh™ Pro-B™ Probiotic Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 may help downregulate TNF-Alpha, IL-6, IL-8, IL-10 and IL-12 (p70) in the neurogenic bladder of spinal cord injured patient with urinary tract infections: a two-case study.
Lactobacillus rhamnosus GR-1 RepHresh™ Pro-B™ Probiotic Probiotic Therapy and Functional Foods for Prevention of Urinary Tract Infections: State of the Art and Science.
Lactobacillus rhamnosus GR-1 RepHresh™ Pro-B™ Probiotic Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a randomised controlled trial.
Lactobacillus rhamnosus GR-1 RepHresh™ Pro-B™ Probiotic Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a study protocol for a randomised controlled trial.
Lactobacillus rhamnosus GR-1 RepHresh™ Pro-B™ Probiotic Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies.
Lactobacillus rhamnosus GR-1 RepHresh™ Pro-B™ Probiotic Probiotics to prevent urinary tract infections: the rationale and evidence.
Lactobacillus rhamnosus GR-1 RepHresh™ Pro-B™ Probiotic Substances released from probiotic Lactobacillus rhamnosus GR-1 potentiate NF-?B activity in Escherichia coli-stimulated urinary bladder cells.
Lactobacillus rhamnosus GR-1 RepHresh™ Pro-B™ Probiotic The role of cranberry and probiotics in intestinal and urogenital tract health.
Lactobacillus rhamnosus GR-1 RepHresh™ Pro-B™ Probiotic The role of lactobacillus probiotics in the treatment or prevention of urogenital infections--a systematic review.
Mutaflor (Escherichia coli strain Nissle 1917) Mutaflor (Canada, Australia, Findland, Germany) In vitro analysis of the bactericidal activity of Escherichia coli Nissle 1917 against pediatric uropathogens.
Mutaflor (Escherichia coli strain Nissle 1917) Mutaflor (Canada, Australia, Findland, Germany) Insights from 100 Years of Research with Probiotic E. Coli
Mutaflor (Escherichia coli strain Nissle 1917) Mutaflor (Canada, Australia, Findland, Germany) The Polyphosphate Kinase of Escherichia coli Is Required for Full Production of the Genotoxin Colibactin.
Streptococcus salivarius K12 BLIS ThroatHealth Oral Probiotics Efficacy of Fluoroquinolone/Probiotic Combination Therapy for Recurrent Urinary Tract Infection in Children: A Retrospective Analysis.
Symbioflor 1 German Apotheke by Paul's Mart Insights from 100 Years of Research with Probiotic E. Coli
Symbioflor 2 German Apotheke by Paul's Mart Insights from 100 Years of Research with Probiotic E. Coli

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.